Medium‐term changes in patients with epilepsy during the COVID‐19 pandemic.
Saved in:
| Title: | Medium‐term changes in patients with epilepsy during the COVID‐19 pandemic. |
|---|---|
| Authors: | Gonzalez‐Martinez, Alicia (AUTHOR), Planchuelo‐Gómez, Álvaro (AUTHOR), Vieira Campos, Alba (AUTHOR), Martínez‐Dubarbie, Francisco (AUTHOR), Vivancos, José (AUTHOR), De Toledo‐Heras, María (AUTHOR) |
| Source: | Acta Neurologica Scandinavica. Oct2021, Vol. 144 Issue 4, p450-459. 10p. |
| Subjects: | COVID-19 pandemic, Social distancing, COVID-19, SARS-CoV-2, People with epilepsy |
| Abstract: | Objectives: The novel coronavirus disease (COVID‐19) pandemic has led to social distancing measures and impaired medical care of chronic neurological diseases, including epilepsy, which may have adversely affected well‐being and quality of life of patients with epilepsy (PWE). The objective of this study is to evaluate the impact of the COVID‐19 pandemic in the levels of anxiety, depression, somnolence, and quality of life using validated scales in PWE in real‐life clinical practice. Materials & Methods: Self‐administered scales of anxiety disorders (GAD‐7), depression (NDDI‐E), somnolence (Epworth Sleepiness Scale; ESS), and quality of life (QOLIE‐31‐P) in PWE treated in a Refractory Epilepsy Unit were longitudinally analyzed. Data were collected before the beginning (December 2019 – March 2020) and during the COVID‐19 pandemic (September 2020–January 2021). Results: 158 patients (85 from the first round and 73 from the second round) 45.0 ± 17.3 years of age, 43.2% women, epilepsy duration 23.0 ± 14.9 years, number of antiepileptic drugs 2.1 ± 1.4, completed the survey. Significant longitudinal reduction of QOLIE‐31‐P (from 58.9 ± 19.7 to 56.2 ± 16.2, p =.035) and GAD‐7 scores (from 8.8 ± 6.2 to 8.3 ± 5.9, corrected p =.024) was identified. No statistically significant longitudinal changes in the number of seizures (from 0.9 ± 1.9 to 2.5 ± 6.2, p =.125) or NDDI‐E scores (from 12.3 ± 4.3 to 13.4 ± 4.4, p =.065) were found. Significant longitudinal increase of ESS (from 4.9 ± 3.7 to 7.4 ± 4.9, p =.001) was found. Conclusions: During the COVID‐19 pandemic, quality of life and anxiety levels were lower in PWE, and sleepiness levels were raised, without seizure change. [ABSTRACT FROM AUTHOR] |
| Copyright of Acta Neurologica Scandinavica is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
Be the first to leave a comment!
